ChemoCentryx Stock News

After Merrill Lynch and Oppenheimer gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy, this time from

After Merrill Lynch and Oppenheimer gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy,

ChemoCentryx Inc (NASDAQ:CCXI) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 2,570,000 shares, a growth of 15.

ChemoCentryx (NASDAQ:CCXI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm currently has a $52.00 ta

Geode Capital Management LLC raised its holdings in shares of ChemoCentryx Inc (NASDAQ:CCXI) by 11.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission.

AQR Capital Management LLC acquired a new stake in ChemoCentryx Inc (NASDAQ:CCXI) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).

Zacks Investment Research lowered shares of ChemoCentryx (NASDAQ:CCXI) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, “

ChemoCentryx Inc (NASDAQ:CCXI) has received an average recommendation of “Buy” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the

Alliancebernstein L.P. increased its stake in shares of ChemoCentryx Inc (NASDAQ:CCXI) by 48.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 88,150 shares of the biopharmaceutic

The market remains unsettled but is moving higher as it expects good things to happen after the hot spots peak. The impact of the pandemic will keep expanding d

Cubist Systematic Strategies LLC reduced its position in shares of ChemoCentryx Inc (NASDAQ:CCXI) by 31.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commis

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

ChemoCentryx (CCXI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ChemoCentryx (CCXI) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

In a report released today, Michelle Gilson from Canaccord Genuity reiterated a Buy rating on Homology Medicines (FIXX), with a price target of $37.00.